9 results about "Lactobacillus jensenii" patented technology

This invention proposes a molecular marker for *Lactobacillus japonicus*, which was deposited on February 7, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 26505. The molecular marker comprises a nucleotide sequence selected from one of the following: (1) the nucleotide sequence shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99%, or higher homology to the nucleotide sequence shown in SEQ ID NO: 24; or (3) a nucleotide sequence having one or more nucleotide substitutions, deletions, or insertions in the nucleotide sequence shown in SEQ ID NO: 24. Using the molecular marker of this invention, not only can the target *Lactobacillus japonicus* be screened quickly and easily, but it can also highly specifically identify the target *Lactobacillus japonicus*, eliminating interference from other strains.

The present invention relates to a synergistic bioactive composition for women's health, and more particularly to compositions comprising Lactobacilli and Lactoferrin for supporting vaginal health. The invention specifically provides a composition comprising Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus fermentum, and Lactoferrin, formulated with one or more pharmaceutically acceptable excipients. The invention further pertains to compositions and kits intended for promoting a balanced vaginal microbiota, maintaining healthy vaginal conditions, and supporting overall vaginal ecosystem stability.

The present invention provides compositions and methods for treating patients. [Solution] The exemplary composition may include a vaginal microbiome composition. The vaginal microbiome composition may include a mixture of bacteria. The bacterial mixture may include Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus rhamnosus.

The present invention relates to vaginal pharmaceutical compositions and methods and uses thereof, including: treating and preventing genital inflammation in a subject; modulating the level of one or more of Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus gardneri, Lactobacillus jensenii, and Lactobacillus iners in the genital microbiome of a subject; and maintaining or improving the integrity of the cervical-vaginal epithelial barrier in a subject.

The present disclosure provides use of a probiotic composition comprising active ingredients including Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus crispatus, and Lactobacillus jensenii in the preparation of a microbial formulation, wherein the microbial formulation is used for: improving the therapeutic effect of an additional drug for treating bacterial vaginosis in the treatment of bacterial vaginosis; improving the prognosis of bacterial vaginosis treated with an additional drug for treating bacterial vaginosis; treating, preventing, mitigating, and / or controlling the recurrence of bacterial vaginosis in a subject; treating, preventing, mitigating, and / or controlling atrophic vaginitis in a subject; improving the Nugent score of a subject; or ameliorating vaginal dryness in a subject.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

The invention discloses a traditional Chinese medicine compound for treating sarcopenia and preparation and application of fermentation liquor of the traditional Chinese medicine compound, and belongs to the field of traditional Chinese medicine application. The traditional Chinese medicine compound for treating sarcopenia is prepared from the following raw materials in parts by weight: 10 to 30 parts of radix astragali seu hedysari, 5 to 25 parts of radix codonopsis, 5 to 25 parts of herba cistanche, 5 to 25 parts of folium cortex eucommiae, 5 to 25 parts of rhizoma polygonati, 5 to 25 parts of radix angelicae sinensis, 5 to 25 parts of fructus crataegi and 5 to 25 parts of roasted fructus hordei germinatus. The traditional Chinese medicine compound fermentation liquor for treating sarcopenia is prepared by the following steps: uniformly mixing the traditional Chinese medicines in parts by weight, adding water, decocting to obtain decoction, and concentrating the decoction to obtain concentrated liquor; inoculating lactobacillus johnsonii, lactobacillus fermentum and bifidobacterium adolescentis into the concentrated solution, and fermenting to obtain fermentation liquor; the traditional Chinese medicine composition has the advantages that the pathological state of sarcopenia is improved through the traditional Chinese medicine composition, and meanwhile a new scheme is provided for the probiotic fermented traditional Chinese medicine decoction.

The application provides a probiotic crystal ball preparation containing lactobacillus jensenii and bifidobacterium longum, which comprises a shell structure and a core structure, wherein the shell structure comprises gelatin, glycerol and water; and the core structure comprises lactobacillus jensenii, bifidobacterium longum and hydrogenated oil. The lactobacillus jensenii has a preservation number of CCTCC NO: M2022172; and the bifidobacterium longum has a preservation number of CCTCC NO: M2019780. The application adopts a double-layer seamless capsule technology with gelatin as the shell material, hydrogenated oil and bacterial powder as the core, so that the probiotics can not be digested by gastric juice and have a high survival rate in the intestinal tract. Moreover, the core of the application uses the screened lactobacillus jensenii VHProbi A17 strain which does not produce hemolysin and cannot dissolve blood cells, and has safety. The lactobacillus jensenii has scavenging effects on DPPH free radicals and hydroxyl radicals, and has a wide antibacterial spectrum.

The present application belongs to the technical field of composite microbial composition, and particularly relates to a female health conditioning composition based on Lactobacillus composite flora and medicinal fungus extract, which comprises composite lactic acid bacteria composed of Lactobacillus crispatus, Lactobacillus jensenii and Lactobacillus reuteri in a specific ratio, a prebiotic composite formed by galactooligosaccharide, fructooligosaccharide and inulin, extracts of Ganoderma lucidum, Hericium erinaceus, Poria cocos, Cordyceps sinensis and white birch fungus, and cranberry extract powder and pineapple powder. The lactic acid bacteria is formed into double-layer microcapsules by electrostatic spraying, and three types of functional components are constructed into a three-layer composite structure by layering and pressing, so as to finally form microcapsule powder. The present application has the characteristics of stable structure, synergistic components and remarkable conditioning effect by targeting regulating vaginal microecology, inhibiting inflammatory response and repairing mucosal barrier, and is suitable for female reproductive tract health management.